Itzykson, Raphaël, Kosmider, Olivier, Renneville, Aline, Gelsi-Boyer, Véronique, Meggendorfer, Manja, Morabito, Margot, Berthon, Céline, Adès, Lionel, Fenaux, Pierre, Beyne-Rauzy, Odile, Vey, Norbert, Braun, Thorsten, Haferlach, Torsten, Dreyfus, François, Cross, Nicholas C.P., Preudhomme, Claude, Bernard, Oliver A., Fontenay, Michaela, Vainchenker, William, Schnittger, Susanne, Birnbaum, Daniel, Droin, Nathalie and Solary, Eric (2013) Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology, 31 (19), 2428-2436. (doi:10.1200/JCO.2012.47.3314). (PMID:23690417)
Abstract
PURPOSESeveral prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations-including ASXL1-have been associated with poor prognosis in univariable analyses. We developed and validated a prognostic score for overall survival (OS) based on mutational status and standard clinical variables. PATIENTS AND METHODSWe genotyped ASXL1 and up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription (RUNX1, NPM1, TP53), and signaling (NRAS, KRAS, CBL, JAK2, FLT3) regulators in 312 patients with CMML. Genotypes and clinical variables were included in a multivariable Cox model of OS validated by bootstrapping. A scoring system was developed using regression coefficients from this model.ResultsASXL1 mutations (P < .0001) and, to a lesser extent, SRSF2 (P = .03), CBL (P = .003), and IDH2 (P = .03) mutations predicted inferior OS in univariable analysis. The retained independent prognostic factors included ASXL1 mutations, age older than 65 years, WBC count greater than 15 ×109/L, platelet count less than 100 ×109/L, and anemia (hemoglobin < 10 g/dL in female patients, < 11g/dL in male patients). The resulting five-parameter prognostic score delineated three groups of patients with median OS not reached, 38.5 months, and 14.4 months, respectively (P < .0001), and was validated in an independent cohort of 165 patients (P < .0001). CONCLUSIONA new prognostic score including ASXL1 status, age, hemoglobin, WBC, and platelet counts defines three groups of CMML patients with distinct outcomes. Based on concordance analysis, this score appears more discriminative than those based solely on clinical parameters.
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.